Granza Bio is a company that developing cancer therapies based on human body's immune system.
Granza Bio has raised $7.1M in total funding. The most recent round was Seed. The last funding was announced in July 2024.
Granza Bio's investors include Y Combinator, Felicis, Pioneer Fund, Refactor, Oxonian Ventures.
Granza Bio is headquartered in San Francisco, United States.
Granza Bio is a company that developing cancer therapies based on human body's immune system.
Granza Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Granza Bio — Funding & Investors." VCBacked, July 3, 2024, https://www.vcbacked.co/company/granza-bio. Accessed July 19, 2026.
VCBacked. (2024). Granza Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/granza-bio
{{cite web |title=Granza Bio — Funding & Investors |url=https://www.vcbacked.co/company/granza-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated